EXAMPLE 1
A male patient, age 41, was treated with intracavernosal injections of a vasodilator, prostaglandin E1, on a regular basis (approximately four to five times per week) over an 18 month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement of an erectile response between 40-75% over a period of several hours, generally 3 to 6 hours. The quantity of medication was adjusted from time to time in accordance with the patient's response, which was monitored at least weekly.
The size of the patient's fully erect penis increased from 5.8 inches to 8.6 inches in length (about an 48% increase) and 3.7 inches to 5.8 inches in girth (about an 56% increase) over the 18-month treatment period. Following the discontinuation of this treatment, the erect penis length remained stable for two years at over 8½ inches. Treatment was re-institued combining intracavernosal injections 3-4 times per week of a mixture of testosterone (0.5 mg) and vasodilators with low dose oral Potaba (500-1000 mg) 3-4 times per day. After a short treatment period of 2½ months, the patient's erect penis was over 9 inches in length, which means he has gained an additional 0.4-0.5 inches in length (about an 6% increase). The total increase in length was therefore about 3.2 inches (about an 55% increase) in length.
EXAMPLE 2
A male patient, age 30, was treated with intracavernosal injections of the vasodilator on a regular basis (approximately four to five times per week) over a 6-month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement over a period of about 3 to 6 hours. The quantity of medication was adjusted in accordance with the patient's response. The potentiator potaba (aminobenzoate) (1000 mg/4 times per day) was administered orally to the patient for the last 60 days of treatment.
The patient's erect penis increased from 5.6 inches to 7.7 inches (about an 38% increase) in length and 3.2 inches to 5.3 inches (about an 65% increase) in girth over the 6-month treatment period.
EXAMPLE 3
A male patient, age 52, was treated with separate intracavernosal injections of vasodilators, Papavarine, phentolamine and prostaglandin E1, on a regular basis, selected from treatments of 0 to 4 times per week, over a 7 month treatment period along with daily subcutaneous injections of a prostaglandin F analogue. A sufficient quantity of vasodilator was administered to maintain a prolonged engorgement of an erectile response greater than 70% for 3.5-5 hours duration. The quantity of medication was adjusted from time to time in accordance with the patient's response, which was monitored initially weekly then monthly once the patient had mastered the IC technique and the responses were consistently of the same duration.
The size of the patient's fully erect penis increased from 5.0 inches to 6.3 inches in length, i.e. about a 26% increase, over the 7-month treatment period. Following the discontinuation of this treatment, the erect penis length remained stable.
EXAMPLE 4
A male patient, age 34, was treated with intracavernosal injections of a triple mix of the vasodilators Atropine, Chlorpromazine and Papavarine on a regular basis (approximately two to five times per week) over a 4-month treatment period. A sufficient-quantity was administered to maintain a prolonged engorgement of 60-90% over a period of about 3 to 4.5 hours. The quantity of medication was adjusted in accordance with the patient's response. The potentiator, Potaba™—potassium aminobenzoate (1000 mg/3-4 times per day) was administered orally starting 1 month before starting the IC injections of the vasodilators Atropine, Chlorpromazine and Papavarine.
After 5 months of treatment the patient's erect penis increased from 6.0 inches to 7.1 inches (about an 18% increase) in length.
EXAMPLE 5
A male patient, age 44, was treated with intracavernosal injections of a quadruple mix of the vasodilators prostaglandin E1, Atropine, Chlorpromazine and Papavarine on a regular basis (approximately two to four times per week) over a 4-month treatment period. A sufficient quantity was administered to maintain a prolonged engorgement over a period of about 3 to 5 hours. The quantity of medication was adjusted in accordance with the patient's response. The potentiator dihydrotestosterone 5%
ointment was administered orally starting two weeks before starting the IC injections of the vasodilators Atropine, Chlorpromazine and Papavarine and prostaglandin.
After 4 months of treatment the patient's erect penis increased from 5.2 inches to 6.5 inches (about a 25% increase) in length.
EXAMPLE 6
A male patient, age 44, was treated with intracavernosal injections of the vasodilator phentolamine on a regular basis (approximately two to four times per week) over a 4-month treatment period. Phentolamine was frequently combined with indirect vasodilating effects of oral Viagra to produce and maintain a prolonged engorgement of 60-90% over a period of about 3 to 5 hours. The quantity of medication was adjusted in accordance with the patient's response. The potentiator dihydrotestosterone gel was administered orally starting two weeks before starting the IC injections of the vasodilators Atropine, Chlorpromazine and Papavarine and prostaglandin.
After 4 months of treatment the patient's erect penis increased from 5.2 inches to 6.5 inches (about a 25% increase) in length.